128 related articles for article (PubMed ID: 16281077)
21. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
22. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
23. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Creutzig U; Zimmermann M; Reinhardt D; Dworzak M; Stary J; Lehrnbecher T
J Clin Oncol; 2004 Nov; 22(21):4384-93. PubMed ID: 15514380
[TBL] [Abstract][Full Text] [Related]
24. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology.
Aladjidi N; Auvrignon A; Leblanc T; Perel Y; Bénard A; Bordigoni P; Gandemer V; Thuret I; Dalle JH; Piguet C; Pautard B; Baruchel A; Leverger G;
J Clin Oncol; 2003 Dec; 21(23):4377-85. PubMed ID: 14645428
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Bloomfield CD; Shuma C; Regal L; Philip PP; Hossfeld DK; Hagemeijer AM; Garson OM; Peterson BA; Sakurai M; Alimena G; Berger R; Rowley JD; Ruutu T; Mitelman F; Dewald GW; Swansbury J
Cancer; 1997 Dec; 80(11 Suppl):2191-8. PubMed ID: 9395033
[TBL] [Abstract][Full Text] [Related]
27. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.
Perel Y; Auvrignon A; Leblanc T; Michel G; Reguerre Y; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Méchinaud F; Lejars O; Piguet C; Couillaud G; Pautard B; Landman-Parker J; Thuret I; Aladjidi N; Baruchel A; Leverger G;
Leukemia; 2005 Dec; 19(12):2082-9. PubMed ID: 16121218
[TBL] [Abstract][Full Text] [Related]
28. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis.
Inaba H; Fan Y; Pounds S; Geiger TL; Rubnitz JE; Ribeiro RC; Pui CH; Razzouk BI
Cancer; 2008 Aug; 113(3):522-9. PubMed ID: 18484648
[TBL] [Abstract][Full Text] [Related]
29. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report.
Entz-Werle N; Suciu S; van der Werff ten Bosch J; Vilmer E; Bertrand Y; Benoit Y; Margueritte G; Plouvier E; Boutard P; Vandecruys E; Ferster A; Lutz P; Uyttebroeck A; Hoyoux C; Thyss A; Rialland X; Norton L; Pages MP; Philippe N; Otten J; Behar C;
Leukemia; 2005 Dec; 19(12):2072-81. PubMed ID: 16136166
[TBL] [Abstract][Full Text] [Related]
30. Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results.
Quintana J; Advis P; Becker A; Beresi V; Campbell M; Vinés EF; García H; Salgado C; Vargas L; Rojas J; Obando M; Neira L; Páez E; Zolezzi P
Leukemia; 2005 Dec; 19(12):2143-6. PubMed ID: 16304574
[No Abstract] [Full Text] [Related]
31. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
Behringer B; Pitako JA; Kunzmann R; Schmoor C; Behringer D; Mertelsmann R; Lübbert M
Ann Hematol; 2003 Jul; 82(7):381-9. PubMed ID: 12756497
[TBL] [Abstract][Full Text] [Related]
32. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
33. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Hurwitz CA; Krance R; Schell MJ; Santana VM; Brenner MK; Ribeirio R; Roberts WM; Mahmoud H; Belt J; Crom W
Leukemia; 1992; 6 Suppl 2():39-43. PubMed ID: 1374492
[TBL] [Abstract][Full Text] [Related]
34. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.
Hasle H; Kerndrup G; Yssing M; Clausen N; Ostergaard E; Jacobsen N; Jacobsen BB
Leukemia; 1996 Aug; 10(8):1269-73. PubMed ID: 8709630
[TBL] [Abstract][Full Text] [Related]
35. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
36. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
[TBL] [Abstract][Full Text] [Related]
37. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
38. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia treatment in patients over 60 years of age. Comparison of symptomatic, palliative, and aggressive therapy.
Doubek M; Palasek I; Brychtova Y; Buchtova I; Mayer J
Neoplasma; 2005; 52(5):411-4. PubMed ID: 16151586
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]